Search

Search Constraints

You searched for: Author/Creator Alroughani, Raed

Search Results

21. Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. (April 2021)

22. Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. Issue 10 (13th June 2016)

23. Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis. (25th October 2022)

24. Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis. (June 2023)

25. Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registry. Issue 12 (30th September 2022)

26. Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. (2nd February 2021)

27. Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies. (December 2020)

28. Expert consensus from the Arabian Gulf on selecting disease-modifying treatment for people with multiple sclerosis according to disease activity. Issue 4 (18th May 2020)

29. Expert consensus from the Arabian Gulf on selecting disease-modifying treatment for people with multiple sclerosis according to disease activity. Issue 4 (18th May 2020)

30. Expert opinion on clinical experience with subcutaneous interferon beta‐1a in multiple sclerosis patients with different disease activity profiles. Issue 5 (26th June 2019)